ARS Pharmaceuticals launched Neffy, the first FDA-approved needle-free epinephrine nasal spray for severe allergic reactions.

FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid symptom relief.

After four weeks, 22.5% of patients taking Spravato achieved remission (score ≤12 on MADRS) compared with 7.6% of patients taking placebo. Spravato nasal spray ... early as 24 hours and at ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in people who have not responded to at least two oral antidepressants.

(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...

21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant ... symptoms as early as 24 hours and at 28 days -- without the need for ...

Share on Pinterest The FDA has approved an esketamine nasal spray for the treatment of depression ... MADRS total score of less than or equal to 12, and 18.3% of those on 56 mg does achieved ...

After four weeks, 22.5 percent of patients taking Spravato achieved remission (score ≤12 on MADRS) compared with 7.6 percent of patients taking placebo. Spravato nasal spray is administered by ...

Opens in a new tab or window The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults ... defined as a MADRS total score of 12 or less. "For more than 6 years, I've seen ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used ... depressive symptoms as early as 24 hours and at 28 days, without the need ...